{
    "nct_id": "NCT02946918",
    "official_title": "Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Age \\> 18 years\n* Presumed AJCC (American Joint Committee on Cancer) tumor Stage I or II\n* Planned total or near-total thyroidectomy\n* Planned goal TSH suppression 0.1-0.5 mU/L for at least 18 weeks postoperatively\n* Normal serum TSH within 12 months preceding surgery\n\nExclusion Criteria:\n\n* AJCC Stage III or greater\n* Undifferentiated, Anaplastic or Medullary Thyroid Cancer\n* Planned postoperative TSH goal other than 0.1-0.5 mU/L\n* History of gastrointestinal malabsorption or gastric bypass surgery\n* Pregnancy\n* Use of medications that alter the absorption or metabolism of levothyroxine\n* Prior use of levothyroxine\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Age > 18 years\n* Presumed AJCC (American Joint Committee on Cancer) tumor Stage I or II\n* Planned total or near-total thyroidectomy\n* Planned goal TSH suppression 0.1-0.5 mU/L for at least 18 weeks postoperatively\n* Normal serum TSH within 12 months preceding surgery",
        "exclusion": "* AJCC Stage III or greater\n* Undifferentiated, Anaplastic or Medullary Thyroid Cancer\n* Planned postoperative TSH goal other than 0.1-0.5 mU/L\n* History of gastrointestinal malabsorption or gastric bypass surgery\n* Pregnancy\n* Use of medications that alter the absorption or metabolism of levothyroxine\n* Prior use of levothyroxine"
    }
}